Cargando...

The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation

Background: The recombinant IL-1 receptor antagonist anakinra—currently approved for the treatment of autoinflammatory diseases—blocks IL-1β-mediated inflammatory signaling. As inflammation is a major driver of cancer, we hypothesized that anakinra might be able to mitigate glioblastoma (GBM) aggres...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Hübner, Max, Effinger, David, Wu, Tingting, Strauß, Gabriele, Pogoda, Kristin, Kreth, Friedrich-Wilhelm, Kreth, Simone
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2020
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7072290/
https://ncbi.nlm.nih.gov/pubmed/32069807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12020433
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!